BIO RAD LABS INC's ticker is BIO and the CUSIP is 090572207. A total of 429 filers reported holding BIO RAD LABS INC in Q2 2024. The put-call ratio across all filers is 1.61 and the average weighting 0.2%.
About BIO RAD LABS INC
Bio-Rad Laboratories, Inc. is a multinational company that specializes in the development and production of life science research and clinical diagnostic products. The company was founded in 1952 and is headquartered in Hercules, California. Bio-Rad has a global presence, with operations in more than 100 countries.
Bio-Rad's life science research products include instruments, reagents, and software used in genomics, proteomics, and cell biology research. The company's clinical diagnostic products include blood typing reagents, quality control products, and infectious disease testing kits.
Bio-Rad has a strong reputation for innovation and quality. The company has received numerous awards for its products, including the Frost & Sullivan Product Line Strategy Leadership Award in 2019 for its Droplet Digital PCR technology.
Bio-Rad's leadership team includes CEO Norman Schwartz, COO Andrew Last, and Chairman of the Board Ronald Hutton. The company has a strong financial position, with a market capitalization of over $16 billion as of August 2021.
Investors interested in Bio-Rad should keep an eye on the company's financial performance, including its revenue growth and profitability. Bio-Rad's strong reputation and innovative products make it a company to watch in the life science research and clinical diagnostic markets.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,669,573 | -27.5% | 46,390 | -8.2% | 0.01% | -25.0% |
| Q1 2024 | $17,487,187 | +5.0% | 50,560 | -1.9% | 0.01% | 0.0% |
| Q4 2023 | $16,649,500 | -13.5% | 51,564 | -3.9% | 0.01% | -25.0% |
| Q3 2023 | $19,238,728 | -6.7% | 53,672 | -1.4% | 0.02% | 0.0% |
| Q2 2023 | $20,626,782 | -30.5% | 54,407 | -12.2% | 0.02% | -27.3% |
| Q1 2023 | $29,679,121 | +12.4% | 61,958 | -1.4% | 0.02% | +4.8% |
| Q4 2022 | $26,410,136 | -3.3% | 62,808 | -4.1% | 0.02% | -4.5% |
| Q3 2022 | $27,324,000 | -15.5% | 65,503 | +0.2% | 0.02% | -12.0% |
| Q2 2022 | $32,352,000 | -14.7% | 65,357 | -2.9% | 0.02% | 0.0% |
| Q1 2022 | $37,923,000 | -25.0% | 67,331 | +0.7% | 0.02% | -19.4% |
| Q4 2021 | $50,532,000 | -42.1% | 66,879 | -42.9% | 0.03% | -42.6% |
| Q3 2021 | $87,321,000 | +0.3% | 117,060 | -13.3% | 0.05% | +5.9% |
| Q2 2021 | $87,017,000 | +14.3% | 135,058 | +1.4% | 0.05% | +6.2% |
| Q1 2021 | $76,100,000 | +30.6% | 133,235 | +33.2% | 0.05% | +26.3% |
| Q4 2020 | $58,291,000 | +35.6% | 99,994 | +19.9% | 0.04% | +31.0% |
| Q3 2020 | $43,003,000 | +7.0% | 83,426 | -6.3% | 0.03% | +3.6% |
| Q2 2020 | $40,185,000 | +30.0% | 89,005 | +0.9% | 0.03% | +3.7% |
| Q1 2020 | $30,919,000 | +9.1% | 88,200 | +15.2% | 0.03% | +22.7% |
| Q4 2019 | $28,332,000 | – | 76,567 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tower House Partners LLP | 190,000 | $63,221,000 | 52.68% |
| Tikvah Management LLC | 149,412 | $49,715,000 | 13.86% |
| Tamarack Advisers, LP | 115,000 | $38,265,000 | 9.97% |
| Miura Global Management | 75,000 | $24,956,000 | 4.39% |
| Asymmetry Capital Management, L.P. | 5,638 | $1,876,000 | 4.02% |
| Intermede Investment Partners Ltd | 194,810 | $64,821,000 | 3.60% |
| Sivik Global Healthcare LLC | 18,000 | $5,989,000 | 3.02% |
| Portolan Capital Management | 79,795 | $26,551,000 | 2.99% |
| SECTOR GAMMA AS | 46,368 | $15,428,000 | 2.61% |
| EASTERLY INVESTMENT PARTNERS LLC | 273,154 | $90,889,000 | 2.55% |